Supernus SVP Horich’s 100,000 stock units convert
The merger converted listed insider awards into successor-company awards; performance awards became time-vesting restricted stock units.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
William Todd Horich reported disposition transactions in this Form 4 filing. At the merger’s effective time on November 2, 2026, Supernus Pharmaceuticals, Inc. SVP, Commercial Operations William Todd Horich’s outstanding equity awards were assumed by Indivior Pharmaceuticals, Inc. (renamed Supernus, Inc.) and automatically converted into corresponding successor-company awards. Reported awards included 100,000 restricted stock units and performance share units covering 5,000 and 3,500 shares. Converted awards retained substantially the same terms and vesting, except performance share units became time-vesting restricted stock units. The 100,000 restricted stock units vest in five installments: 40% at merger closing and 15% at each of the next four anniversaries.
Insider Trade Summary
Other: 264,125 shares
Other
15 txns
Insider
Horich William Todd
Role
SVP, Commercial Operations
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Restricted Stock Unit F1, F2 | 100,000 | $0.00 | $0.00 |
| Other | Performance Share Unit F3, F1, F4 | 5,000 | $0.00 | $0.00 |
| Other | Performance Share Unit F3, F1, F5 | 3,500 | $0.00 | $0.00 |
| Other | Restricted Stock Unit F6, F1, F7 | 6,250 | $0.00 | $0.00 |
| Other | Restricted Stock Unit F6, F1, F8 | 2,500 | $0.00 | $0.00 |
| Other | Restricted Stock Unit F6, F1, F9 | 3,375 | $0.00 | $0.00 |
| Other | Restricted Stock Unit F6, F1, F10 | 3,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F1, F11 | 13,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F1, F12 | 14,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F1, F13 | 17,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F1, F14 | 18,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F1, F15 | 20,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F1, F16 | 25,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F1, F17 | 20,000 | $0.00 | $0.00 |
| Other | Employee Stock Option (Right to Buy) F1, F18 | 13,500 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Unit — 0 contracts (Direct);
Performance Share Unit — 0 contracts (Direct);
Employee Stock Option (Right to Buy) — 0 contracts (Direct)
Holdings Before and After:
Restricted Stock Unit, 115,125 to 0 contracts (Direct);
Performance Share Unit, 8,500 to 0 contracts (Direct);
Employee Stock Option (Right to Buy), 140,500 to 0 contracts (Direct)
Footnotes (18)
- F1. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F2. These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in five installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.
- F3. Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
- F4. On February 19, 2025, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on May 3, 2025.
- F5. On February 18, 2026, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on July 15, 2026.
- F6. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F7. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
- F8. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
- F9. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
- F10. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.
- F11. The option vests in four equal annual installments beginning on February 14, 2019.
- F12. The option vests in four equal annual installments beginning on February 22, 2020.
- F13. The option vests in four equal annual installments beginning on February 19, 2022.
- F14. The option vests in four equal annual installments beginning on February 22, 2023.
- F15. The option vests in four equal annual installments beginning on February 23, 2024.
- F16. The option vests in four equal annual installments beginning on February 22, 2025.
- F17. The option vests in four equal annual installments beginning on February 19, 2026.
- F18. The option vests in four equal annual installments beginning on February 18, 2027.
Key Figures
Restricted stock units: 100,000 units
Performance share units: 5,000 shares
Performance share units: 3,500 shares
+3 more
6 metrics
Restricted stock units
100,000 units
Award entry converted at the merger effective time on November 2, 2026
Performance share units
5,000 shares
Award entry converted at the merger effective time on November 2, 2026
Performance share units
3,500 shares
Award entry converted at the merger effective time on November 2, 2026
Award share conversion multiplier
1.5401
Merger award conversion; converted share counts rounded down
Restricted stock units vesting at closing
40%
The 100,000-unit award’s vesting schedule
Restricted stock units vesting at each anniversary
15%
At each of the four anniversaries after merger closing
Key Terms
equity award, exchange ratio, restricted stock units, performance share units, +1 more
5 terms
equity award financial
"each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior"
An equity award is a form of pay where a company gives employees, executives or other stakeholders the right to own or buy company shares—either immediately or after meeting certain conditions. Think of it like receiving slices of the company pie now or coupons to claim slices later; it matters to investors because it affects ownership dilution, executive incentives and reported compensation costs, and signals how management is being rewarded and retained.
exchange ratio financial
"multiplied by the 1.5401 exchange ratio"
The exchange ratio is the number used to decide how many shares of one company you get for each share you own in another company during a merger or acquisition. It’s like a recipe that tells you how to swap shares fairly, ensuring both companies’ values are balanced. This ratio matters because it determines how ownership divides between the companies' shareholders.
restricted stock units financial
"These restricted stock units ("RSUs") are settled in common stock upon vesting"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
vesting financial
"40% of the RSUs vest upon the closing of the merger-of-equals transaction"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many awards were converted for William Todd Horich at SUPN?
Reported award entries included 100,000 restricted stock units and performance share units covering 5,000 and 3,500 shares. These awards were assumed by Indivior Pharmaceuticals, Inc. and converted into corresponding awards of Supernus, Inc. at the merger’s effective time on November 2, 2026.
What exchange ratio applied to the SUPN award conversion?
Each converted award covered Supernus, Inc. shares equal to the prior award’s Supernus Pharmaceuticals share count multiplied by 1.5401, rounded down. The per-share exercise price was divided by 1.5401 and rounded up to the nearest whole cent.
How do William Todd Horich’s 100,000 SUPN restricted stock units vest?
The 100,000 restricted stock units vest in five installments: 40% upon the merger closing, then 15% upon each of the one-, two-, three- and four-year anniversaries of closing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
